MGC Pharmaceuticals has reached a major milestone after receiving formal authorisation to sell its CannEpil medical cannabis based epilepsy treatment in Australia through specialist prescribers under the Authorised Prescriber Scheme. This signals the start of commercial-scale production of CannEpil at MGC’s EU GMP certified facility in Slovenia. CannEpil is expected to generate $1m in annualised revenues from an initial base of about 100 patients.
11/10/2018 - 15:32
MGC gains tick of approval cannabis epilepsy drug
By Matt Birney
11/10/2018 - 15:32
Related Data & Insights
-
-
Rank Company Revenue th Argent BioPharma $1.7m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
01 Dec 2023
Board Moves December 1, 2023
28 Jul 2023
Board Moves July 28, 2023
30 Jun 2023
MGC Pharma sacks senior staffer
07 Jun 2023
Board Moves May 31 to June 2, 2023
01 Mar 2023
Board Moves March 1, 2023
03 Jan 2023
Board Moves January 3, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX